{"id":"W3037506839","doi":"10.1016/j.jtho.2020.06.015","title":"A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":645,"is_retracted":false,"has_abstract":false,"ca_institutions":"Kingston General Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Bayer; Servier; Astellas Pharma; Les Laboratories Pierre Fabre; Merck Sharp and Dohme; Takeda Pharmaceuticals U.S.A.; F. Hoffmann-La Roche; AbbVie; Merck; Spectrum Pharmaceuticals; Celgene; Novartis; Sanofi; PharmaMar; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer; Roche; Astellas Pharma US","keywords":"Medicine; Pembrolizumab; Oncology; Placebo; Protocol (science); Internal medicine; Chemotherapy; Randomized controlled trial; Immunotherapy; Cancer; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00334019,0.002606576,0.004550397,0.0006165733,0.000738985,0.001700511,0.001490584,0.002531687,0.01490289],"category_scores_gemma":[0.003827158,0.001126132,0.003883235,0.0005590419,0.001466359,0.001716893,0.0006899064,0.004546938,0.002526619],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00120874,"about_ca_system_score_gemma":0.001776345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001616442,"about_ca_topic_score_gemma":0.003784032,"domain_scores_codex":[0.998401,0.0008852864,0.0001194863,0.000294263,0.00008700644,0.0002129909],"domain_scores_gemma":[0.9985978,0.0005028627,0.0002769301,0.0001676255,0.0001408396,0.0003139766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.992406,0.001093952,0.0001250711,0.0004727185,0.001367142,0.00001185515,0.00001714644,0.0001444785,0.0007305168,0.00007245074,0.0004313483,0.003127418],"study_design_scores_gemma":[0.9896563,0.00882508,0.0003565027,0.00002055762,0.0005748197,0.000006974734,0.000007400129,0.0001063373,0.00009228595,0.00008375267,0.0002627626,0.000007232856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9304753,0.0158752,0.003810495,0.002750975,0.003517709,0.02503532,0.007104706,0.0005921992,0.01083796],"genre_scores_gemma":[0.9666236,0.003438142,0.003742996,0.002404016,0.0007950405,0.01252187,0.002853559,0.00007007911,0.007550616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01490289,"threshold_uncertainty_score":0.04985511,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0330906876140015,"score_gpt":0.3841235725741152,"score_spread":0.3510328849601138,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}